Equities research analysts at Roth Capital started coverage on shares of Acura Pharmaceuticals (NASDAQ: ACUR) in a research note issued to investors on Tuesday, Analyst Ratings Network.com reports. The firm set a “buy” rating on the stock.

Shares of Acura Pharmaceuticals ( NASDAQ: ACUR ) opened at 2.26 on Tuesday. Acura Pharmaceuticals has a one year low of $1.06 and a one year high of $4.50. The stock’s 50-day moving average is currently $2.35. The company’s market cap is $104.8 million.

Acura Pharmaceuticals (NASDAQ: ACUR) last posted its quarterly earnings results on Monday, March 4th. The company reported ($0.86) EPS for the quarter.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies.